TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:28
Aurinia Pharmaceuticals Inc. ( AUPH ) https://www.auriniapharma.com
9.25USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-0.11%
AUPH
SPY
32.66%
-60.35%
AUPH
SPY
108.59%
-56.82%
AUPH
SPY
302.52%
AUPH
159.83%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1347.27
1006.01
0.76
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-59.74
6.47
3.47
2.80
0.00
115.61
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
21.17
89.13
3.98
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.5888
-7.20
1.95
1.16
Other Earnings and Cash Flow Stats:
Aurinia Pharmaceuticals Inc. ( AUPH ) Net Income TTM ($MM) is -22.55
Aurinia Pharmaceuticals Inc. ( AUPH ) Operating Income TTM ($MM) is -32.69
Aurinia Pharmaceuticals Inc. ( AUPH ) Owners' Earnings Annual ($MM) is -33.84
Aurinia Pharmaceuticals Inc. ( AUPH ) Current Price to Owners' Earnings ratio is -39.09
Aurinia Pharmaceuticals Inc. ( AUPH ) EBITDA TTM ($MM) is -22.91
Aurinia Pharmaceuticals Inc. ( AUPH ) EBITDA Margin is 3.98%
Capital Allocation:
Aurinia Pharmaceuticals Inc. ( AUPH ) has paid 0.00 dividends per share and bought back -2.804 million shares in the past 12 months
Aurinia Pharmaceuticals Inc. ( AUPH ) has reduced its debt by 0.724 million USD in the last 12 months
Capital Structure:
Aurinia Pharmaceuticals Inc. ( AUPH ) Interest-bearing Debt ($MM) as of last quarter is 6
Aurinia Pharmaceuticals Inc. ( AUPH ) Annual Working Capital Investments ($MM) are 8
Aurinia Pharmaceuticals Inc. ( AUPH ) Book Value ($MM) as of last quarter is 388
Aurinia Pharmaceuticals Inc. ( AUPH ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Aurinia Pharmaceuticals Inc. ( AUPH ) has 36 million in cash on hand as of last quarter
Aurinia Pharmaceuticals Inc. ( AUPH ) has 78 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aurinia Pharmaceuticals Inc. ( AUPH ) has 145 common shares outstanding as of last quarter
Aurinia Pharmaceuticals Inc. ( AUPH ) has 0 million USD of preferred stock value
Academic Scores:
Aurinia Pharmaceuticals Inc. ( AUPH ) Altman Z-Score is 3.86 as of last quarter
Aurinia Pharmaceuticals Inc. ( AUPH ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
Aurinia Pharmaceuticals Inc. ( AUPH ) largest shareholder is owning shares at 0.00 ($MM) value
TANG KEVIN(an insider) Bought 500000 shares of Aurinia Pharmaceuticals Inc. ( AUPH ) for the amount of $4545000.00 on 2024-12-09
7.06% of Aurinia Pharmaceuticals Inc. ( AUPH ) is held by insiders, and 44.75% is held by institutions
Aurinia Pharmaceuticals Inc. ( AUPH ) went public on 1999-01-26
Other Aurinia Pharmaceuticals Inc. ( AUPH ) financial metrics:
FCF:28.85
Unlevered Free Cash Flow:-45.67
EPS:0.39
Operating Margin:21.17
Gross Profit Margin:89.13
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:14.79
Beta:1.16
Buffet's Owners Earnings:-33.84
Price to Owner's Earnings:-39.09
About Aurinia Pharmaceuticals Inc. ( AUPH ) :
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.